Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

Tapan M. Kadia, Christopher Benton, Harry P. Erba, Mitul Gandhi, Moshe Y. Levy, Mary-Elizabeth M. Percival, Matthew Ulrickson, Habte Yimer, Min Yu, Zi Chen, Jing Wang, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai

Blood (2022) 140 (Supplement 1): 11659–11660.

https://doi.org/10.1182/blood-2022-162627

Published: 2022

Journal Articles

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Blood (2021) 138 (Supplement 1): 895.

https://doi.org/10.1182/blood-2021-150519

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Maro Ohanian, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2021-150049

Published: 2021

Journal Articles

Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study

Moshe Y. Levy, Deepa Jagadeesh, Zhanet Grudeva-Popova, Marek Trněný, Wojciech Jurczak, Halyna Pylypenko, Marc André, Sunita Dwivedy Nasta, Dalit Rechavi-Robinson, Sara Toffanin, Sandrine Micallef, Antoine Attinger, Elisabeth Rouits, Marie-Claude Roubaudi-Fraschini, Panos Orfanos, Mariola Dymkowska, Heidi Nauwelaerts, Sherida Woei-a-Jin

Blood (2021) 138 (Supplement 1): 526.

https://doi.org/10.1182/blood-2021-145102

Published: 2021

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 1284.

https://doi.org/10.1182/blood-2021-146666

Published: 2021

Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2742.

https://doi.org/10.1182/blood-2021-148385

Published: 2021

Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2757.

https://doi.org/10.1182/blood-2021-145903

Published: 2021

Journal Articles

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2021-146681

Published: 2021

Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2021-148544

Published: 2021

Journal Articles

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations

David Andorsky, Sarah Tomassetti, Yehuda E. Deutsch, E Randolph Broun, Ghayas C. Issa, Moshe Y. Levy, Michael W. Deininger, Rodrigo Maegawa, Alok Shrestha, Michael J. Mauro

Blood (2021) 138 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2021-147337

Published: 2021

Journal Articles

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Mazyar Shadman, MD MPH, Jeff P Sharman, MD, Moshe Y. Levy, MD, Jamal Misleh, MD, Syed F. Zafar, MD, Benjamin B. Freeman, MD, John M. Burke, MD, Jennifer L. Cultrera, MD, Habte A. Yimer, MD, Dih-Yih Chen, MD, Xiaoping Zhang, MD, Aileen Cohen, MD PhD, Sunhee Ro, PhD, Jane Huang, MD, Ian W. Flinn, MD PhD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-134621

Published: 2020

Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-134948

Published: 2020

Journal Articles

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Alexander M. Lesokhin, MD, Moshe Y. Levy, MD, Andrew P. Dalovisio, MD, Nizar J. Bahlis, MD, Melhem Solh, MD, Michael Sebag, MD PhD FRCPC, Andrzej Jakubowiak, MD PhD, Yogesh S. Jethava, MBBS, MD FRCPath, MRCP, Caitlin L. Costello, MD, Michael P. Chu, MD, Michael R. Savona, MD, Cristina Gasparetto, MD, Suzanne Trudel, MD MSC, FRCPC, Jeffrey Chou, MD PhD, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Heike I. Krupka, PhD PMP, Noopur S. Raje, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133355

Published: 2020

Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Holger W Auner, MD PhD, Maria Gavriatopoulou, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Meletios A Dimopoulos, Irina Kryachok, Professor, Halyna Pylypenko, MD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria Mateos, MD PhD, Michele Cavo, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Paul G. Richardson, MD, Sebastian Grosicki, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137303

Published: 2020

Journal Articles

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-137574

Published: 2020

Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137154

Published: 2020

Journal Articles

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali S. Advani, Daniel J. DeAngelo, Tibor J. Kovacsovics, Anand Jillella, Dale Bixby, Moshe Y. Levy, Megan M. O’Meara, Phoenix A. Ho, Jenna Voellinger, Anthony S. Stein

Blood (2018) 132 (11): 1125–1133.

https://doi.org/10.1182/blood-2018-03-841171

Published: 2018

Journal Articles

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Amir T. Fathi, MD, Harry P. Erba, MD PhD, Jeffrey E. Lancet, MD, Eytan M. Stein, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Roland B. Walter, MD PhD MS, Anjali Advani, MD, Daniel J. DeAngelo, MD PhD, Tibor J. Kovacsovics, MD, Anand P Jillella, MD, Dale L. Bixby, MD PhD, Moshe Y Levy, MD, Megan M. O'Meara, MD, Phoenix Ho, MD, Anthony S. Stein, MD

Blood (2016) 128 (22): 591.

https://doi.org/10.1182/blood.V128.22.591.591

Published: 2016

Journal Articles

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Harry P. Erba, MD PhD, Moshe Y Levy, MD, Sumithira Vasu, MBBS, Anthony S. Stein, MD, Amir T. Fathi, MD, Michael B. Maris, MD, Anjali Advani, MD, Stefan Faderl, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Roland B. Walter, MD PhD, Jay Yang, MD, William B. Donnellan, MD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Farhad Ravandi, MD

Blood (2016) 128 (22): 211.

https://doi.org/10.1182/blood.V128.22.211.211

Published: 2016

NARROW

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only